Kailera Therapeutics, Inc. (KLRA) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Kailera Therapeutics, Inc. (KLRA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.84B, listed on NASDAQ, employing roughly 145 people, carrying a beta of 0.00 to the broader market. Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. Led by Ronald C. Renaud Jr., public since 2026-04-17.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for KLRA as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.